Fig. 1.

Schematic diagram of different therapeutic approaches targeting HER2+ tumor cells. A) Trastuzumab/Pertuzumab therapy promotes ADCC. B) Vaccine effect of Anti-HER2 Antibodies. Strategies to potentiate anti-HER2 ADCC: C) By blocking NK inhibitory receptors. D) By enhancing NK activation. E) By combination with Checkpoints inhibitors F) By FcR affinity alteration. Created with BioRender.com. NK cell: Natural Killer cell; ADDC: Antibody-dependent cellular cytotoxicity; TAAs: Tumor-associated antigens; HER2bsAb: HER2 Bispecific Antibodies.